Literature DB >> 26174192

Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias.

António Morais1, Marília Beltrão2, Oksana Sokhatska2, Diogo Costa3, Natalia Melo4, Patricia Mota4, Agostinho Marques4, Luís Delgado5.   

Abstract

INTRODUCTION: Accurate diagnosis of idiopathic pulmonary fibrosis (IPF) has important therapeutic and prognostic implications and would be greatly aided by reliable diagnostic biomarkers as IPF has sometimes overlapping features with other interstitial lung diseases (ILD).
OBJECTIVES: To explore the value of serum metalloproteinases (MMP) 1 and 7 levels in the differential diagnosis of IPF with other ILD.
METHODS: MMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47 IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspecific Interstitial Pneumonia (iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared using the Mann-Whitney U test.
RESULTS: MMP-1 was significantly higher in IPF than non-IPF UIP (P = .042) and sarcoidosis (P = .027). MMP-7 was significantly higher in IPF than controls (P < .001), non-IPF UIP (P = .003), secNSIP (P < .001), and sarcoidosis (P < .001). The Area Under the Curve for IPF versus other ILD was 0.63 (95%CI, 0.53-0.73) for MMP-1, 0.73 (95%CI, 0.65-0.81) for MMP-7, and 0.74 (95%CI, 0.66-0.82) for MMP-1/MMP-7 combined. Sensitivity and specificity for MMP-7 cutoff = 3.91 ng/mL was 72.3% and 66.3%, respectively, Positive Predictive Values = 52.3% and Negative Predictive Values = 82.4%.
CONCLUSIONS: MMP-1 and particularly MMP-7 serum levels were significantly higher in IPF than in non-IPF UIP, the main entity in differential diagnosis. The value of these biomarkers as additional tools in a multidisciplinary approach to IPF diagnosis needs to be considered and further explored.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Idiopathic interstitial pneumonias; Idiopathic pulmonary fibrosis; Metalloproteinase 1; Metalloproteinase 7; Metalloproteinases; Sarcoidosis

Mesh:

Substances:

Year:  2015        PMID: 26174192     DOI: 10.1016/j.rmed.2015.06.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

1.  SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.

Authors:  Argyrios Tzouvelekis; Guoying Yu; Christian L Lino Cardenas; Jose D Herazo-Maya; Rong Wang; Tony Woolard; Yi Zhang; Koji Sakamoto; Hojin Lee; Jae-Sung Yi; Giuseppe DeIuliis; Nikolaos Xylourgidis; Farida Ahangari; Patty J Lee; Vassilis Aidinis; Erica L Herzog; Robert Homer; Anton M Bennett; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

2.  Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia.

Authors:  Chatmanee Lertudomphonwanit; Reena Mourya; Lin Fei; Yue Zhang; Sridevi Gutta; Li Yang; Kevin E Bove; Pranavkumar Shivakumar; Jorge A Bezerra
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

3.  Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.

Authors:  Argyris Tzouvelekis; Jose D Herazo-Maya; Martin Slade; Jen-Hwa Chu; Giuseppe Deiuliis; Changwan Ryu; Qin Li; Koji Sakamoto; Gabriel Ibarra; Hongyi Pan; Mridu Gulati; Danielle Antin-Ozerkis; Erica L Herzog; Naftali Kaminski
Journal:  Respirology       Date:  2016-10-19       Impact factor: 6.424

Review 4.  From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis.

Authors:  Catherine A Bonham; Mary E Strek; Karen C Patterson
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

5.  Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.

Authors:  Yoichiro Aoshima; Yasunori Enomoto; Shigeki Muto; Shiori Meguro; Hideya Kawasaki; Isao Kosugi; Tomoyuki Fujisawa; Noriyuki Enomoto; Naoki Inui; Yutaro Nakamura; Takafumi Suda; Toshihide Iwashita
Journal:  Lung       Date:  2021-03-26       Impact factor: 2.584

6.  Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers.

Authors:  Katharine M Irvine; Leesa F Wockner; Isabell Hoffmann; Leigh U Horsfall; Kevin J Fagan; Veonice Bijin; Bernett Lee; Andrew D Clouston; Guy Lampe; John E Connolly; Elizabeth E Powell
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

Review 7.  Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.

Authors:  John N Shumar; Abhimanyu Chandel; Christopher S King
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

Review 8.  Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.

Authors:  Anna Stainer; Paola Faverio; Sara Busnelli; Martina Catalano; Matteo Della Zoppa; Almerico Marruchella; Alberto Pesci; Fabrizio Luppi
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

9.  PEDF, a pleiotropic WTC-LI biomarker: Machine learning biomarker identification and validation.

Authors:  George Crowley; James Kim; Sophia Kwon; Rachel Lam; David J Prezant; Mengling Liu; Anna Nolan
Journal:  PLoS Comput Biol       Date:  2021-07-21       Impact factor: 4.475

Review 10.  Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Sandra Cabrera; Mariel Maldonado; Moisés Selman
Journal:  Respir Res       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.